Hansa Biopharma AB (HNSA) — Cash Flow-to-Debt Ratio
Hansa Biopharma AB (HNSA) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2025, meaning its operating cash flow of Skr-111.70 Million could theoretically repay 0% of its total liabilities (Skr1.28 Billion) in one year. See HNSA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hansa Biopharma AB Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Hansa Biopharma AB across 17 annual periods. Also explore HNSA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hansa Biopharma AB (2008–2024)
Year-by-year debt coverage analysis for Hansa Biopharma AB. For market capitalisation and broader financial context, see how much is Hansa Biopharma AB worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.49x | Skr-674.88 Million | Skr1.39 Billion | ▲ +23.8% |
| 2023 | -0.64x | Skr-755.65 Million | Skr1.19 Billion | ▼ -37.5% |
| 2022 | -0.46x | Skr-502.73 Million | Skr1.08 Billion | ▲ +75.4% |
| 2021 | -1.89x | Skr-481.17 Million | Skr255.24 Million | ▼ -24.9% |
| 2020 | -1.51x | Skr-290.27 Million | Skr192.37 Million | ▲ +54.3% |
| 2019 | -3.30x | Skr-334.77 Million | Skr101.42 Million | ▼ -37.1% |
| 2018 | -2.41x | Skr-204.56 Million | Skr84.94 Million | ▲ +20.2% |
| 2017 | -3.02x | Skr-150.10 Million | Skr49.75 Million | ▲ +13.9% |
| 2016 | -3.51x | Skr-94.56 Million | Skr26.98 Million | ▲ +23.8% |
| 2015 | -4.60x | Skr-57.80 Million | Skr12.56 Million | ▲ +12.2% |
| 2014 | -5.24x | Skr-23.62 Million | Skr4.51 Million | ▼ -79.7% |
| 2013 | -2.92x | Skr-14.87 Million | Skr5.10 Million | ▲ +63.9% |
| 2012 | -8.07x | Skr-20.63 Million | Skr2.56 Million | ▼ -84.1% |
| 2011 | -4.39x | Skr-27.14 Million | Skr6.19 Million | ▼ -36.6% |
| 2010 | -3.21x | Skr-18.09 Million | Skr5.64 Million | ▼ -207.9% |
| 2009 | -1.04x | Skr-13.79 Million | Skr13.23 Million | ▲ +72.3% |
| 2008 | -3.77x | Skr-15.58 Million | Skr4.13 Million | — |